

ACCURAY

Accuray Innovation Driven Growth Strategy

Investor Day

October 26, 2020



Forward Looking Statements

This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing

Safe Harbor Statement

Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: expectations regarding new product enhancements or offerings, including the expected timing of product launches and releases; our growth drivers and strategic priorities, including expectations and plans to execute upon such drivers and priorities; expectations regarding the radiotherapy and neurosurgery market opportunity; expectations regarding our installed base; expectations related to the market opportunity in China and its ability to grow our business; expectations related to our joint venture in China; expectations regarding the trend toward ultra-hypofractionation and our ability to capitalize on those trends; our ability to continue to innovate and execute on our product roadmap; our ability to expand the addressable market of our products; our expectations regarding the Radiation Oncology Alternative Payment Model as well as reimbursement trends and our ability to capitalize on the same; expectations regarding system revenue contributions from China; our belief that our products offer clinicians and patients significant benefits over other radiation therapy systems in the market; and our expectations regarding long-term market expansion opportunities. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “may,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: the effects of the COVID-19 pandemic on our business, financial condition, results of operations or cash flows; our ability to achieve widespread market acceptance of our products, including new product offerings and improvements; our ability to develop new products or enhance existing products to meet customers’ needs and compete favorably in the market; our ability to effectively integrate and execute the joint venture; our ability to realize the expected benefits of the joint venture; risks and uncertainties related to future Type A and B license announcements in China; risks inherent in international operations; our ability to effectively manage our growth; our ability to maintain or increase our gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; our ability to meet the covenants under our credit facilities; our ability to convert backlog to revenue; and other risks identified under the heading “Risk Factors” in our annual report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on August 25, 2020, and as updated periodically with our other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Medical Advice Disclaimer

Accuray Incorporated as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual results may vary.

Financial Disclosure

The information contained in this presentation provided by radiation oncologists and other healthcare professionals, including any accompanying oral commentary, represent the genuine experience of such healthcare professionals and may not necessarily represent the views of Accuray Incorporated or the institutions with which such healthcare professionals are affiliated. An honorarium was provided to such healthcare professionals for their participation.



Agenda

- Welcome
- Company Vision and Growth Strategy
- Market Dynamics and Long-Term Growth Catalysts
- Enabling Technology and Product Roadmap
- Q & A

Radiation **Therapy...**



Powerful

Non-Invasive


Easy Patient Treatment Experience

**Potential for Improved Outcomes and
Quality of Life**

New Therapeutic Option

Hope

Our Vision



To **expand** the
curative **power** of
radiation therapy to
improve as
many lives as
possible.

- Broader treatment options
- Beyond oncology
- Global patient access

- Enable advanced treatments
- Survival, long term outcomes
- Quality of life

- Precision technology
- Focused, agile organization
- Partnerships

- Focused resources
- Expertise
- Best in class

Accuray Growth Strategy: Deliver More. Better. Faster.



Strong Foundation for Long-Term Growth

- Experienced leadership team
- Focused R&D investment to drive innovation
- Differentiated go-to-market strategy in China
- Growing operational leverage

Differentiated Solutions

- Unique, ultra-precision platforms
 - Robotic, non-coplanar delivery
 - Helical imaging and delivery
- Advanced dual-platform technologies
 - Synchrony®
 - New ClearRT™ imaging
 - VOLO™
- Exciting future product roadmap

Strong Favorable Market Catalysts

- Underpenetrated global market
- Increased use of shorter, higher dose treatments/new reimbursement
- Aging installed base ripe for new system upgrade
- China market acceleration

Experienced Leadership Team



Josh Levine

President & CEO



Suzanne Winter

Chief Commercial Officer
SVP R&D

Medtronic, GE, Toshiba



Shig Hamamatsu

Chief Financial Officer

Cepheid, PWC



Scott Chapman

SVP Global Service

GE Healthcare



Jesse Chew

General Counsel

Wilson Sonsini



Michael Hoge

SVP Global Operations

GE, Generac



Patrick Spine

Chief Administrative Officer

PRA, Hospira, Eaton


Why Customers Choose Accuray

Ultra-Precise, Radiation Therapy Planning and Delivery Platforms



CyberKnife® Platform

- Robotic design
- SRS/SBRT
- Versatility across neuro and radiation oncology



Enables

Outcomes
Quality of life
Patient experience
Differentiation




TomoTherapy® Platform

- Helical imaging & delivery
- Broad patient treatment with SBRT growth
- Dedicated to oncology


Operating Earnings and Installed Base Recent Trends

Improving Fundamentals and Growing Installed Base

Operating Leverage



Growing Installed Base




Operating leverage expected to drive long-term profitability growth

Generated >\$200M+ of annual service revenue for the past six fiscal years

Innovate to Drive Market Penetration, Share Gain & IB Renewal

Cadence of Annual Product Launches Over Next 3 Years



1. As of June 30, 2020, we held exclusive field of use licenses or ownership of approximately 472 U.S. and foreign patents, and approximately 129 U.S. and foreign patent applications.

Strategy to Accelerate Long-Term Growth Trajectory

Accelerate Growth

Transform Culture and
Begin Innovation Driven
Growth

Reposition for Success

FY2018 – FY2019


- Enhanced leadership team
- Won 50 out of 58 China Type A licenses and established China joint venture
- Reset cost structure to increase operating leverage
- Focused R&D investments to drive innovation pipeline

FY2020 – FY2021 Plan

- Developed strategic roadmap/ vision on key growth opportunities
- Leverage Radixact® System + Synchrony® and ClearRT™, and CyberKnife® S7™, to win in the market
- Execute on China Type A revenue ramp
- Continue to build on our global infrastructure and operations

FY2022+ Plan

- Consistent cadence of new products and partnerships
- Expand addressable markets and drive share gain
- Drive additional growth from China Type B opportunity
- Capitalize on operating leverage to drive greater profits and cash flows



Favorable Market Dynamics and Long-Term Growth Catalysts

Suzanne Winter
Chief Commercial Officer
Senior Vice President, R&D

Favorable Market Dynamics and Long-Term Growth Catalysts

Global Radiotherapy Market Overview

China Market Opportunity and our Differentiated Strategy

Treatment Modality Trend (SBRT vs. Conventional)

RO-APM Update / How Accuray will Benefit

Underpenetrated Global Radiotherapy Market¹

A Growing Addressable Market

18 MILLION



New Cases Of Cancer
Worldwide In 2018

50-60%



Of Cancer Patients
Worldwide Would Benefit
From Radiation Therapy

30%



Currently Receive
Radiation Therapy

21,800²



Total Number Of Linacs
Needed By 2035

+7,700



Number Of New Linacs
Needed To Meet Expected
Demand For Radiation
Therapy in 2035

+150%




Expected Increase In
Number Of Patients
Receiving Radiation
Therapy By 2035

1. <https://www.who.int/news-room/fact-sheets/detail/cancer>; The Lancet Oncology Commission – “Expanding Global Access to Radiotherapy, Volume 16 September 2015 Edition Radiotherapy in Cancer Care: Facing the Global Challenge, IAEA 2017
2. 21,800 includes 14,100 expected replacement systems and 7,700 new systems

Neurosurgery Market Opportunity

- Growing global interest in stereotactic radiosurgery¹
 - RSS/ISRS: >1,400 members
- Non-invasive, surgical alternative
- Aging Gamma Knife installed base²
- Growing interest in movement disorders³
- Capital equipment budget constraints expected to provide opportunity for shared systems⁴

Global Neurostimulation Devices Market 2014–2019 (US\$ million)³



1. J Neurosurg 130:1055–1064, 2019

2. Elekta Annual Report. Gamma Knife is a registered trademark of Elekta


3. Tech Navio Analysis

4. MK Dean, AA Ahmed et al. "Distribution of dedicated stereotactic radiosurgery systems in the United States." AppliedRadiationOncology.com. March 2019


Replacement and Upgrade Opportunity

Developed Markets Aging Installed Base Upgrade to Advanced Capabilities

Age of Accuray Installed Base



- Median age of total US radiation therapy installed base: ≥ 8 years¹
- 82% of purchases are replacements¹
- New capabilities driving purchase decisions




China

China: Unprecedented Long-Term Growth Opportunity

China Expected Cancer Incidence



China's lack of access to Radiotherapy: Linac Installed Base by Country



1. Chen W, et al. Cancer statistics in China, 2015

China Joint Venture

Accuray's Differentiated Strategy

"MADE IN CHINA 2025" INITIATIVE

Locally branded and manufactured product well-aligned with local policies

MARKET ACCESS

Broad JV commercial infrastructure and access to hospitals

UNIQUE POSITIONING

Competitive advantage as the only radiation therapy company with local Chinese partner

EXPANDS TYPE B OPPORTUNITY

Expand commercial strategy and portfolio to address large Type B market



- Established in July 2019 with China Isotope and Radiation Corp. (CIRC) as partner
- 49% owned by Accuray, 51% owned by CIRC
- Led by Roger Cao (JV CEO), former Accuray APAC GM
- ~100 employees as of October 2020
- Headquartered in Tianjin, China

China JV Status Update

Key Achievements and Future Milestones

Key Operational Achievements

- Manufacturing facility construction complete
- Customer Training Center activated
- 20+ sub-dealer network established
- 40+ service engineers transferred from TomoKnife (legacy distributor)

Future Milestones

- Manufacturing commencement of locally-branded product expected in ~15 months
- Expand to ~200 employees by FY23
- Joint development of Type B product portfolio to expand market coverage in ~24 months




China Market Opportunity

Accuray Strong Win Rate in Type A 1st Round

QUOTA TYPE	ACCURAY PRODUCT	ACCURAY WIN RATE
TYPE A "PREMIUM" 188	Radixact® Tomo HDA™ and HD® CyberKnife®	50 OUT OF 58 ¹ 86% of Type A licenses awarded to Accuray systems in the first round
TYPE B "CORE" 1,451	Tomoh® New JV System ²	TBD

1. Represents the number of China Type A licenses granted to Accuray systems as of October 26, 2020.

2. Under development and not yet available for sale.




Clinical Trends Toward Ultra-Hypofractionation

Factors Accelerating Shorter Treatments¹

U.S.: 2014 – 2019

- Treatment system consolidation
- Treatment demand increasing
- Reimbursement pressure
- Patient/provider impact due to COVID
- Clinical evidence and guidelines


Accuray Technology Positioned to Capitalize on these Trends



Purchase Decisions Prioritizing Advanced Technologies

U.S.: 2014 – 2019

Clinical sites adopting advanced delivery methods¹



Reimbursement Changes

Radiation Oncology Alternative Payment Model (RO-APM)

Shawn Prince
Senior Director, Patient Access

RO-APM Market Catalyst

~3-year process initiated by Congress and CMS

Starts January 1, 2021 and runs through December 31, 2025

Projected to save ~\$230 million by shifting payment to episodic, diagnosis-based payments

Providers randomly selected by zip code

- 30% of all radiation episodes paid by traditional Medicare will be paid under this model

16 diagnoses representing ~90% of indications

Accuray technologies are expected to thrive in new environment

- Specifically designed to deliver ultra-hypofractionated treatments
- Enable treatments that are more cost efficient for the provider to deliver
- Provides the potential to reduce CAPEX and OPEX – treat more patients with less machines
- Improve patients clinical and financial experiences

RT Services Included in RO-APM Bundle

Service

Accuray Innovation

Treatment Planning

Accuray Precision[®] Treatment Planning System

Technical Prep & Special Services

InCise[™] Multileaf Collimator, TQA[™] Software,
Synchrony[®] Respiratory Vest

Radiation Delivery

CyberKnife[®], Radixact[®] Systems

Treatment Management

PreciseART[®] Adaptive Radiation Therapy

Accuray Capabilities Align With Key Diagnoses in RO-APM

Cancer Type	ASTRO / NCCN Guidelines		Percent of Radiation Therapy Cases**
	Mod-HF	Ultra-HF	
Head & Neck		✓*	5.6%
Brain Mets	✓	✓	6.3%
Bone Mets		✓	9.3%
Prostate	✓	✓	17.7%
Lung	✓	✓	18.9%
Breast	✓		21.8%

~80%
of All
RT Cases


HF – Hypofractionation

* For recurrences

** Clinical Mix – Medicare Claims (2015 – 2017)

Beyond CMS: Commercial Payers Mandate Hypofractionation

Example: Prostate Cancer



Blue Shield of California⁴

- Prove medical necessity for conventional treatment

eviCore⁵

- Radiation Benefit Manger (RBM)
- Authorize only 28 or fewer sessions

Excellus⁶

- Authorize only 28 or fewer sessions

1. Blue Shield of California - <https://www.blueshieldca.com/bsca/about-blue-shield/corporate/fast-facts.sp>

2. eviCore - <https://www.evicore.com/-/media/files/evicore/microsites/implementation/oscar/oscar-medical-oncology-and-specialty-drug-provider-orientation-presentation.pdf>




3. Excellus - https://news.excellusbcbs.com/news-room/releases/-/asset_publisher/26WPXjkp2c3P/content/excellus-bcbs-updates-on-covid-19-coronavirus-3-19-20

4. https://www.evicore.com/-/media/files/evicore/clinical-guidelines/solution/radiation-oncology/healthplan/evicore_radiationoncology_v30_final_eff092120_pub062920_upd071020.pdf

5. https://www.blueshieldca.com/bsca/bsc/public/common/PortalComponents/provider/StreamDocumentServlet?fileName=PRV_IMRT_Prostate_eff_11.20.2020.pdf

6. <https://provider.excellusbcbs.com/en/resources/news/article?articleId=281960146&classPK=281960142>

Provider Strategy: Ultra-Hypofractionation Increases Capacity



1. Treatment capacity was determined based on internal Accuray model
 2. Revenue determined by internal Accuray model

Ultra-Hypofractionation Supports Shift From Volume to Value

Accuray's innovative technologies have the potential to deliver more value

Increase annual number of patients treated


Shorter total treatment times

Decrease treatment related costs

Improved total cost of ownership

Provide high quality patient outcomes and experiences


Reduced toxicities due to tighter margins




Enabling Technology and Product Roadmap

Corey Lawson
Vice President, Product Strategy

Aligning Innovation to Growth Opportunities






Radixact[®] Roadmap Programs




Radixact[®]

Ultra-Precise Helical Delivery | Treats Simple to Complex



ACCURAY



Synchrony[®]

Managing Motion With Synchrony®

Comfortable for the Patient and Easy for Clinical Staff

NATURAL PATIENT BEHAVIOR

Greater Patient Comfort
Improving the Patient Experience

EFFICIENT CONTINUOUS DELIVERY

More Efficient Treatments to More
Patients at a Lower Cost
Potential for Increased Profitability



MINIMAL MARGINS

Potential for Better Clinical
Outcomes with Fewer Side Effects
Freedom to Ultra-Hypofractionate
Treatment Delivery

Managing Patient Respiration: Conventional Methods

Patient Restraint:
Abdominal Compression



Trained Breathing Device:
Enable Predictable Gating




Synchrony® on the Radixact® System



Enables Continuous Delivery and Patient Comfort



- Imaging enables in-treatment monitoring of target location
- External camera enables real-time monitoring of breathing cycle
- System creates an AI-driven predictive model of target location with breathing cycle



AI-driven predictive model of target position with respiration




Synchrony[®] on the Radixact[®] System

Enables Continuous Delivery and Patient Comfort



- Imaging enables in-treatment monitoring of target location
- External camera enables real-time monitoring of breathing cycle
- System creates a model of the target location with breathing cycle
- Dynamic jaws and binary MLC enable the system to synchronize delivery with known target location




Synchrony[®] on the Radixact[®] System

Patient Case Highlight: SBRT Lung¹



- **Patient:** 45-year old male with lung metastasis
- **SBRT:** 54 Gy in 3 fractions (18 Gy/fx)
- **No fiducials:** reduces patient risk of collapsed lung (pneumothorax and hemothorax)
- **PTV:** 18.3 cc, margin 5 mm (no ITV); 7 mm motion
30% reduction in volume when compared to ITV method
- **Beam-on time:** 9 minutes
In-room time: 19 minutes
Compared to 40-60 minutes for a gated delivery
- **Advantage:** Synchrony[®] allowed clinicians to increase target dose by 4.7% while simultaneously reducing mean lung dose by 12.1%




*Patient image and plan data provided by
Froedtert & the Medical College
of Wisconsin, Milwaukee, WI*

Synchrony[®] on the Radixact[®] System

Clinical Advantages



Synchrony[®]



Fast

Beam ON throughout range of motion


Precise

Tighter margins enabled when beam follows the target

Enables Ultra-Hypofractionation

Deliver more dose to the target, in less time, with greater precision

Conventional Methods



Slow


Beam OFF much of the motion cycle (Gating)

Compromised

Wider margins compensate for slow speed (ITV)

Prolongs Fractionation


Less dose per fraction to let normal surrounding tissue recover



Prof. Umberto Ricardi

Chairman of Radiation Oncology and Dean of the School of Medicine at the University of Turin in Turin Italy, as well as the Director of the Department of Oncology at Health and Science Academic Hospital in Turin. Today, he's using Radixact with Synchrony to deliver extremely precise lung SBRT treatments to the most fragile lung cancer patients using tight margins to preserve healthy lung tissues – without the use of fiducials in most cases.






Dr. Chikao Sugie

Completed clinical training in the Department of Radiology at the Graduate School of Medical Sciences and Medical School, Nagoya City University. He then went on to become an Associate Professor in the Department of Radiology at Nagoya City University. He pursued research on radiation biology and lung cancer radiation as subspecialties. He is currently the Vice Director of the Department of Radiology at the Japanese Red Cross Nagoya Daini Hospital, a leading center providing advanced radiation treatments in Japan.





ClearRT™ Imaging for the Radixact® System

510(k) Pending

Imaging Center of Excellence

Experienced and Knowledgeable Team



○ Strategic investment in imaging

○ High density of imaging companies and expertise

○ Significant impact with iterative reconstruction and Synchrony® development programs

○ Introduction of ClearRT™ Helical kVCT Imaging¹

Clinical Value of Improved Imaging

See More – Plan More – Do More



Pre-Delivery

- Ensures proper patient positioning prior to each fraction
- Favors efficient setup, workflow, departmental efficiency

Intra-Delivery

- Verifies ongoing tumor and beam alignment (Synchrony®)

Post-Delivery

- Measures dose delivered to the target and surrounding healthy tissue
- Becomes the simulation image for replanning, when required

More Clinical Confidence

ClearRT™ Helical kVCT¹

First on Radixact® System

Quality Leadership

- Bringing diagnostic-like quality images into the RT workflow

Unmatched Flexibility

- Largest field-of-view (50cm) and scan length (up to 135cm)
- Fast 1-meter in 1-minute for long field registration
- No learning curve, familiar user interface
- Maintains MV imaging mode for those with metal implants
- Supports various applications (Synchrony®, Adaptive, Simulation/Planning)
- Remains affordable to the market

Unique Technology

- 15 patent disclosures submitted or in process, using the Radixact® System's unique slipping platform advantage




ClearRT™ Helical kVCT¹

Radixact® System's Unique Helical Platform Advantage



High Speed

Broad Imaging Beam
Moderate Scatter



High Quality

Narrow Imaging Beam
Low Scatter



1. ClearRT Helical kVCT Technology is 510(k) Pending

ClearRT™ Helical kVCT¹

Unique Advantages Over Other Offerings

Excellent uniformity and low noise across entire image
Conebeam CT prone to scatter artifact

Exceptional Spatial Resolution
MR prone to geometric distortion

Low-contrast anatomy such as skin, fat, and soft tissue easily visualized

1.35 Meters

Conebeam 40cm

1. ClearRT Helical kVCT Technology is 510(k) Pending
2. Porcine images courtesy of the University of Wisconsin-Madison, Department of Human Oncology

ClearRT™ Helical kVCT¹

Unique Advantages Over Other Offerings



MVCT



ClearRT™
(High Speed Mode)



Diagnostic CT

(Note: Acquisitions performed several minutes apart, NOT exactly the same slice)

1. ClearRT Helical kVCT Technology is 510(k) Pending
2. Porcine image

ClearRT™ Plus Helical kVCT¹

Executing on Vision

In Development

Further Enhances Soft-Tissue Contrast


- Directly competes with MR-linac on soft tissue contrast, but without magnetic deformation of anatomy (excellent spatial resolution)
- Native image enables tissue density measurements, allowing for direct dose measurement and monitoring for adaptive workflows etc.

Upgradeable, Same Workflow

- Merging with MV imaging for unsurpassed anatomic visualization of patients with metal implants or obese patients
- Simultaneously image and treat within the same plane for real-time QA
- Potential to take Synchrony® fiducial free tracking beyond lung
- Same workflow, supported by the same staff

Maintains a Unified Portfolio

- Phased modular imaging advancements offered as upgrades
- Near-term kVCT imaging is only the first step




1. ClearRT Plus Technology is under development – This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions

ClearRT™ Helical kVCT

Executing on the Imaging Vision and Roadmap

Soft Tissue Visualization and Fiducial-Free Tracking Almost Anywhere in the Body



1. ClearRT Helical kVCT Technology is 510(k) Pending

2. ClearRT Plus Technology is under development – This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions

TOMO VOLO™1

Improved Treatment Planning and Operational Efficiency

In Development

Auto pitch and modulation factor

Snapshots

Real-time tradeoff exploration

The screenshot displays the TOMO VOLO™1 software interface for a patient named GR_UE_HeadNeck3. The interface includes several key components:

- Target Goals Table:**

VOI	Goal Type	Weight	Specified Dose (Gy)	Achieved Dose (Gy)	Volume (cm³)	Volume (%)
PTV54p	Max	1.0	68.00	68.26	0.00	0.0
PTV54p	Min	1.0	54.00	54.91	20.15	95.0
PTV54LN	Max	1.0	66.00	67.06	0.00	0.0
PTV54LN	Min	1.0	54.00	54.41	165.05	95.0
PTV54LN	Max	1.0	66.00	65.76	0.00	0.0
- Critical Goals Table:**

VOI	Goal Type	Weight	Specified Dose (Gy)	Achieved Dose (Gy)	Volume (cm³)	Volume (%)
GlnD_Submand_L	Max	1.0	24.00	11.26	11.14	45.0
GlnD_Submand_L	Max	1.0	50.00	19.36	0.00	0.0
Lobe_Temporal_L	Max	1.0	30.00	15.96	3.73	40.0
Lobe_Temporal_L	Max	1.0	60.00	17.22	0.00	0.0
Lobe_Temporal_R	Max	1.0	58.00	61.67	0.00	0.0
Brachialplexus_R	Max	1.0	59.00	56.32	0.00	0.0
NeckAveid	Max	1.0	64.00	23.43	0.00	0.0
- Dose Statistics Table:**

Name	Dose (Gy)	Dose (%)	Volume (cm³)	Volume (%)	Criteria (2-click to edit)
PTV54p	54.00	81.8	20.68	97.5	
PTV59.4	59.40	90.0	90.62	98.9	
PTV54LN	54.00	81.8	156.70	96.0	
PTV66	66.00	100.0	29.92	94.3	
PTV54	54.00	81.8	4.98	97.9	
Lobe_Temporal_R	57.79	87.6	0.10	0.2	
Cochlea_R	42.74	64.8	0.10	79.4	

“Speed is quite impressive. Increased speed is always with improved plan quality...
Beginners can pick it up faster.” – Dr. Kai Schubert, Dept of Radiooncology and Radiotherapy, University Clinic Heidelberg

1. Tomo Volo technology is under development - This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions.

Value Segment/China

Emerging Market System Needs

In Development

Product Priorities

- High throughput / workflow efficiency
Reduced total cost of care
- Base clinical capabilities with options
- Upgradeability path
- Targeting calendar 2022 availability



Radixact® System Innovation Roadmap Summary

Synchrony®
SBRT
Expansion

Beam follows moving targets in real-time, speeding delivery while improving delivery quality

ClearRT™
Fundamental to Adaptive Therapy¹

Image the largest/longest fields with diagnostic-like quality, quickly


VOLO™
Fast Planning, Fast Treatments²

Improved Operational Efficiency



Radixact® platform:
foundation for therapy innovation

1. ClearRT Helical kVCT Technology is 510(k) Pending
2. VOLO Technology is under development.



CyberKnife[®] Roadmap Programs



CyberKnife[®] S7[™]

Industry-Leading Precision | Confident, Effective SRS And SBRT Treatment Delivery

Unique Robotic Platform

Dose Minimization To
Organs At Risk

Moving or Stationary
Targets

Flexible Dose Sculpting



Fast Treatment Planning


Fast Treatment Delivery

Quick Installation

Industry-Leading Uptime

Pioneering NeuroRadiosurgery With CyberKnife®

A Practical Guide to Build an SRS Program



38 Authors
14 Countries



**Covers all intracranial
and spine indications**

CyberKnife[®] S7[™] System

Neuro Package

Neuro Package
In Development

- **Frameless or Frame-Based¹**
Choose based upon clinical need; maintain familiarity to those transitioning from other delivery systems
- **Neuro Planning**
Integrates workflows and planning conventions recognized by neurosurgeons
- **Oligometastatic Treatment**
Ability to treat multifocal disease with greater efficiency
- **Collimation**
Tailored to common neurosurgical case demands



1. Frame-based Neuro Technology is under development - This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions.


CyberKnife[®] S7[™] System

ClearRT[™] Volumetric Imaging¹

Volumetric Imaging
In Development


Integrated 3D Volumetric Imaging

- **Planning**
Supports efficient same-day simulation / plan / treat workflow
- **Registration**
Enables imaging the patient in treatment position, increasing speed and confidence in initial setup and registration
- **Advanced Adaptive**
Opens the door to advanced Adaptive features, taking into account patient changes throughout the course of therapy
- **Availability**
Targeting calendar 2023




1. CyberKnife ClearRT Volumetric Imaging Technology is under development - This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions.

CyberKnife® System Innovation Roadmap Summary




1. Frame-based Neuro technology is under development
2. ClearRT Helical KVCT Technology is 510(k) Pending



Dr. Chris Loiselle


Board-certified Radiation Oncologist who practices at the Swedish Medical center in Seattle WA. Dr. Loiselle received his medical degree from John's Hopkins University and completed his residency in Radiation Oncology from the University of Washington Medical Center. Dr. Loiselle currently serves as the Director of Radiosurgery at the Swedish Medical Center.






Adaptive Therapy

Innovation Convergence



High-Level Adaptive Workflow

Clinical Decision Tree




Clinical Decisions

- 1. Treat
- 2. Shift Dose, Recalculate, and Treat
- 3. Adapt Plan Offline
- 4. Adapt Plan Online¹
- 5. Real-time Delivery Adaptation

1. Online Adaptation is under development – This does not reflect a commitment to deliver products, software, features, functionality, or upgrades, and should not be relied upon in making purchasing decisions.

Adaptive Radiotherapy Strategy

Building Block Technologies Provide Sound Benefits Along The Way




Commitment to Seamless Integration

Powerful Partnerships for Customer Ease of Integration


- **Oncology Information Systems**
Ensure connectivity between Accuray products and established / establishing OIS offerings
- **Treatment Planning**
Expand interoperability with RaySearch's RayStation
- **Collaborative Effort**
Support customers' demand for best-in-class treatment systems that aggregate information into a contiguous patient record
- **Hospital Information System (HIS) Through Partnerships**






Q&A






Closing Remarks

Expanding the Curative Power of Radiation Therapy to Improve as Many Lives as Possible





Thank you

ACCURAY

